Literature DB >> 20376456

[Hepatic metastases in CUP (cancer of unknown primary) and painful amaurosis].

A Klingenstein1, A R Haug, M M Nentwich, E M Messmer, U C Schaller.   

Abstract

A 63-year-old woman presented with a 9-month history of painful amaurosis of the left eye caused by hemophthalmos. She was already undergoing chemotherapy for histopathologically proven liver metastases caused by an assumed melanoma. The location of the primary tumor was unknown. Whole-body FDG-PET/CT staging identified a lesion with characteristically malignant uptake in the region of the left eye as the primary tumor. After enucleation, a primary uveal melanoma was verified that expressed the serological marker melanoma inhibitory activity (MIA). FDG-PET/CT was able to successfully align hepatic metastases due to CUP with local ophthalmologic diagnostic findings and led to a correct diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20376456     DOI: 10.1007/s00347-010-2131-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  9 in total

1.  Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma.

Authors:  Madhavi Kurli; Shantan Reddy; Lawrence B Tena; Anna C Pavlick; Paul T Finger
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

2.  Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.

Authors:  A B Francken; M J Fulham; M J Millward; J F Thompson
Journal:  Eur J Surg Oncol       Date:  2006-06-09       Impact factor: 4.424

3.  Immunophenotypic differences between uveal and cutaneous melanomas.

Authors:  Satori Iwamoto; Robert C Burrows; Robert E Kalina; David George; Michael Boehm; Mark A Bothwell; Rodney Schmidt
Journal:  Arch Ophthalmol       Date:  2002-04

4.  Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.

Authors:  K Strobel; B Bode; R Dummer; P Veit-Haibach; D R Fischer; L Imhof; S Goldinger; Hans C Steinert; G K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

5.  Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.

Authors:  Ingrid Haritoglou; Armin Wolf; Tanja Maier; Christos Haritoglou; Rüdiger Hein; Ulrich Christoph Schaller
Journal:  Ophthalmologica       Date:  2009-03-06       Impact factor: 3.250

Review 6.  Cutaneous malignant melanoma metastatic to the eye, lids, and orbit.

Authors:  Caroline Rosenberg; Paul T Finger
Journal:  Surv Ophthalmol       Date:  2008 May-Jun       Impact factor: 6.048

7.  Serum markers to detect metastatic uveal melanoma.

Authors:  Vivian Barak; Shachar Frenkel; Inna Kalickman; Andrew J Maniotis; Robert Folberg; Jacob Pe'er
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

8.  Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging.

Authors:  T Beyer; U Pietrzyk; C Knoess; S Vollmar; K Wienhard; L Kracht; A Bockisch; S Maderwald; H Kühl; M Fitzek
Journal:  Nuklearmedizin       Date:  2008       Impact factor: 1.379

9.  Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.

Authors:  Thomas C Kwee; Robert M Kwee
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.